Create your personal profile and easily find a job you love.
Sign upCrescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity.
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity.
This company page was generated automatically and therefore features only limited information. Find out more about Crescendo Biologics UK on their company website:
This company page was generated automatically and therefore features only limited information. Find out more about Crescendo Biologics UK on their company website:
When you connect, your chance of being approached for an opportunity at this company is 3 times higher.
View what's on offer:
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.